Nantes, France, December 20, 2010 – TcLand Expression SA, a leading company focused on Personalized Medicine today announced the appointment of Peter Payne as its Chief Business Officer and head of US Operations.
TcLand Expression is developing breakthrough personalized medicine companion diagnostics in immune mediated disorders and is clinically validating personalized medicine biomarkers for tolerance in liver transplantation.
“We are particularly happy to welcome Peter Payne to TcLand Expression. Peter is a senior executive with rare and extensive international experience in business operations and deal making in Europe and in the USA. His arrival will significantly accelerate the potential of the company to enter into major strategic industrial partnerships and corporate alliances, and leverage the value of the company’s disruptive technologies”, said TcLand Expression CEO Alain Huriez, MD.
“I’m delighted to be joining the TcLand team at this time”, commented Peter Payne. “The company has made significant progress since its inception and is now well poised to have considerable impact on patient outcomes and stakeholder value. This is an exciting time for TcLand and I am looking forward to being a part of the next phase of the company’s development”, added Peter.
Peter Payne, 51, joins TcLand Expression following a distinguished career within Quintiles Transnational Corp where he held a variety of senior operational and Business Development positions in Europe and the USA: he was latterly Vice President Corporate Development and responsible for the development of relationships at a strategic level with a portfolio of biopharmaceutical companies, Venture Capital funds, and other financial institutions. Peter’s experience in directing in-depth portfolio analysis to create proactive development and commercialization strategies enabled him to propose innovative business models and customized solutions to help biopharma companies manage risk. Early on in his career, Peter also held roles at Wellcome Research Labs, Sterling Drug and Glaxo Group Research, all based in the UK. Peter holds an Honors Degree in Pharmacology from the University of Manchester and has completed post-graduate training at the University of North Carolina and the University of Chicago Graduate School of Business.
TcLand Expression
TcLand Expression is an acknowledged pioneer in the discovery, the development and the validation of gene expression biomarkers for unmet medical needs in transplantation and auto-immune disease. The company benefits from an exceptional scientific and clinical environment. For more information, please visit our website: www.tcland-expression.com
Contacts
Alain Huriez, CEO Caroline Carmagnol TcLand Expression ALIZE RP Phone: +33 2 40 35 89 99 + 33 6 64 18 99 59 ahuriez@tcland-expression.com caroline@alizerp.com
